Novo Nordisk Partners with Hims & Hers<\/p>\n
Novo Nordisk has decided to sell its weight-loss drug through Hims & Hers’ telehealth platform, following a lawsuit over patent violations regarding a compounded version of semaglutide products<\/a>.<\/p>\n In February, Hims & Hers Health agreed to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers’ international presence<\/a>.<\/p>\n Hims and Hers 2026 Guidance Below Expectations<\/p>\n Hims & Hers Health reported fourth-quarter revenue of $617.82 million, falling short of analyst estimates of $619.22 million<\/a>.<\/p>\n However, the company did beat earnings expectations with a reported 8 cents per share, surpassing estimates of 3 cents per share.<\/p>\n Hims & Hers also provided guidance<\/a> for first-quarter revenue between $600 million and $625 million, which is below the analyst estimate of $653.12 million.<\/p>\n The company expects fiscal 2026 sales<\/a> of $2.7 billion-$2.9 billion compared to the consensus of $2.74 billion, with adjusted EBITDA between $300 million and $375 million.<\/p>\n Mixed Technical Signals<\/p>\n The stock is currently trading 41.6% above its 20-day simple moving average (SMA) but is 30.4% below its 100-day SMA, indicating a mixed short-term and long-term technical picture.<\/p>\n Over the past 12 months, shares have decreased by 54.34% and are currently positioned closer to their 52-week lows than highs.<\/p>\n The RSI is at 30.87, which is considered neutral territory, while the MACD shows a value of -2.7530, with the signal line at -3.3415, indicating bullish momentum as the MACD is above the signal line.<\/p>\n This combination suggests that while the stock is not in an oversold condition, there is potential for upward movement.<\/p>\n Key Resistance: $25.00<\/p>\n Key Support: $15.00<\/p>\n Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target<\/a> of $32.40. Recent analyst moves include:<\/p>\n Barclays: Overweight (Lowers Target to $25.00) (Feb. 25)<\/p>\n Morgan Stanley: Equal-Weight (Lowers Target to $21.00) (Feb. 25)<\/p>\n Leerink Partners: Market Perform (Lowers Target to $17.50) (Feb. 24)
\nBenzinga Edge Ranks HIMS Mixed<\/p>\n